Bharat Biotech's oral cholera vaccine, Hillchol, has demonstrated successful Phase III clinical trial results, proving ...

Bharat Biotech’s oral cholera vaccine, Hillchol, aims to ease a critical global shortfall, with the world currently lacking ...

Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III ...

In conclusion, Dr. Jitendra Singh reiterated that India possesses an “enabling milieu” for biotech growth, propelled by ...

Bharat Biotech's Hillchol OCV, effective against cholera serotypes, aims to provide affordable, accessible vaccines for ...

In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and ...

Hyderabad-based Bharat Biotech International Ltd. has claimed that its oral cholera vaccine (OCV) under development, Hillchol ...

Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III ...

Imperial College launches India Connect Fund. Bengaluru, May 21 (UNI) In a landmark move to deepen Indo-UK scientific cooperation, Imperial College London on Tuesday launched the ...

Bharat Biotech to launch Hillchol, its oral cholera vaccine, amid a global shortage. With Phase III trials completed and 200M ...

Dr. Jelena Begovic, President of the ICGEB Board of Governors, praised India's efforts in advancing space biotechnology.